🧬 One of the benefits of RNA therapies: by injecting code instead of peptides, the body does the manufacturing internally, over long periods of time. Today’s news: Moonwalk’s oversubscribed $70M Series B with Eli Lilly to fund first-in-human studies. PharmaExec: “Across multiple preclinical studies, Moonwalk demonstrated reductions in both body weight and fat mass while still preserving lean muscle mass, and without reducing food intake.” “Moonwalk's programs are designed to selectively deliver siRNA therapeutics directly to adipose tissue, enabling precise modulation of novel, non-incretin pathways underlying obesity. The company combines AI reasoning with human genetics, epigenomics and multi-omics discovery and proprietary tissue-targeting chemistry to unlock previously inaccessible biology, with the goal of developing first-in-class medicines.” "Obesity is one of the most significant global health challenges, and Moonwalk is pursuing a fundamentally different approach to treating it," said Rick Gerson, CEO of Alpha Wave Global. "By targeting adipose tissue directly, Moonwalk may redefine how obesity is treated by delivering therapies with the potential for durable efficacy, lean muscle preservation and infrequent dosing."” — from • Deeper dive: • Company: